1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013

Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 95 pages

Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI). Skin And Skin Structure Infections (SSSI) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI).
- A review of the Skin And Skin Structure Infections (SSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin And Skin Structure Infections (SSSI) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Skin And Skin Structure Infections (SSSI) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Skin And Skin Structure Infections (SSSI) 8
Skin And Skin Structure Infections (SSSI) Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Skin And Skin Structure Infections (SSSI) Therapeutics - Products under Development by Companies 16
Companies Involved in Skin And Skin Structure Infections (SSSI) Therapeutics Development 17
GlaxoSmithKline plc 17
Rib-X Pharmaceuticals, Inc. 18
Paratek Pharmaceuticals, Inc. 19
Affinium Pharmaceuticals, Inc. 20
Bharat Biotech International Limited 21
Nabriva Therapeutics AG 22
Cempra Pharmaceuticals, Inc. 23
Trius Therapeutics, Inc. 24
Tetraphase Pharmaceuticals Inc. 25
Durata Therapeutics Inc. 26
Skin And Skin Structure Infections (SSSI) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
dalbavancin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
GSK-1322322 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
AFN-1252 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
AFN-1252 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
lysostaphin - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
omadacycline tosylate - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
BC-3781 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
BC-7013 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
delafloxacin - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
radezolid - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
oritavancin disphosphate - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
fusidic acid - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
tedizolid phosphate - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
avarofloxacin - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
eravacycline - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Bismith-Thiol Compound For Acute Wound Infection - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Skin And Skin Structure Infections (SSSI) Therapeutics - Drug Profile Updates 61
Skin And Skin Structure Infections (SSSI) Therapeutics - Discontinued Products 84
Skin And Skin Structure Infections (SSSI) Therapeutics - Dormant Products 85
Skin And Skin Structure Infections (SSSI) - Product Development Milestones 86
Featured News and Press Releases 86
Jul 02, 2013: The Medicines Company Announces Positive Results for Solo II Trial of Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections 86
Jun 12, 2013: Trius Therapeutics Announces Publication Of Antibiotic Safety Study In Antimicrobial Agents And Chemotherapy 87
May 30, 2013: Cempra Receives Patent Allowance For US Patent Application On Taksta Loading Dose Formulation 87
May 14, 2013: Rib-X Pharma Initiates Delafloxacin Global Phase III Clinical Trial In Patients With Acute Bacterial Skin And Skin Structure Infections 88
Apr 29, 2013: Durata Therapeutics Announces Presentation Of New Data Demonstrating In Vitro Potency Of Dalbavancin Against Bacterial Pathogens At 23rd Annual ECCMID Meeting 89
Apr 29, 2013: Trius Therapeutics Presents Clinical Data On Experimental Antibiotic Tedizolid At ECCMID Meeting 90
Apr 24, 2013: Durata Therapeutics To Present Two Dalbavancin Posters At 23rd Annual ECCMID Meeting 90
Apr 23, 2013: Trius Therapeutics To Present Experimental Antibiotic Study Results Of Tedizolid Phosphate At ECCMID Meeting 91
Mar 20, 2013: Affinium Pharma Announces Positive Results From Phase IIa Clinical Trial Of Oral AFN-1252 In Acute Bacterial Skin and Skin Structure Infections 92
Mar 20, 2013: Affinium Pharma Announces Positive Results From Phase IIa Clinical Trial Of Oral AFN-1252 In Acute Bacterial Skin and Skin Structure Infections 92
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 95
Disclaimer 95



List of Tables

Number of Products Under Development for Skin And Skin Structure Infections (SSSI), H2 2013 8
Products under Development for Skin And Skin Structure Infections (SSSI) - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Comparative Analysis by Late Stage Development, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
GlaxoSmithKline plc, H2 2013 17
Rib-X Pharmaceuticals, Inc., H2 2013 18
Paratek Pharmaceuticals, Inc., H2 2013 19
Affinium Pharmaceuticals, Inc., H2 2013 20
Bharat Biotech International Limited, H2 2013 21
Nabriva Therapeutics AG, H2 2013 22
Cempra Pharmaceuticals, Inc., H2 2013 23
Trius Therapeutics, Inc., H2 2013 24
Tetraphase Pharmaceuticals Inc., H2 2013 25
Durata Therapeutics Inc., H2 2013 26
Assessment by Monotherapy Products, H2 2013 27
Assessment by Stage and Route of Administration, H2 2013 29
Assessment by Stage and Molecule Type, H2 2013 31
Skin And Skin Structure Infections (SSSI) Therapeutics - Drug Profile Updates 61
Skin And Skin Structure Infections (SSSI) Therapeutics - Discontinued Products 84
Skin And Skin Structure Infections (SSSI) Therapeutics - Dormant Products 85



List of Figures

Number of Products under Development for Skin And Skin Structure Infections (SSSI), H2 2013 8
Products under Development for Skin And Skin Structure Infections (SSSI) - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Late Stage Products, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 27
Assessment by Route of Administration, H2 2013 28
Assessment by Stage and Route of Administration, H2 2013 29
Assessment by Molecule Type, H2 2013 30
Assessment by Stage and Molecule Type, H2 2013 31



Companies Mentioned

GlaxoSmithKline plc
Rib-X Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
Affinium Pharmaceuticals, Inc.
Bharat Biotech International Limited
Nabriva Therapeutics AG
Cempra Pharmaceuticals, Inc.
Trius Therapeutics, Inc.
Tetraphase Pharmaceuticals Inc.
Durata Therapeutics Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Biguanide Market

  • January 2017
    8 pages
  • Biguanide  

    Genetic  

    Chromosome  

View report >

Biological Therapy Industry in the US

  • January 2017
    9 pages
  • Vaccine  

  • United States  

View report >

Therapy Market in the UK

  • January 2017
    19 pages
  • Therapy  

  • United Kingdom  

View report >

Related Market Segments :

Therapy

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.